News | March 11, 2025
Syngene acquires first US biologics facility for $36.5 million
Overall investment in the US facility is estimated around US$50 million
Overall investment in the US facility is estimated around US$50 million
Biocon Biologics remains committed to global standards of quality and compliance
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
The inspection concluded with the issuance of a form 483 with five observations
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Lonza plans to invest approximately CHF 500 million to upgrade the facility
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
